Search hospitals > South Dakota > Rapid City
Black Hills Regional Eye Institute
Claim this profileRapid City, South Dakota 57701
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Degeneration
Conducts research for Diabetic Macular Edema
Conducts research for Glaucoma
Conducts research for Cystoid Macular Edema
83 reported clinical trials
2 medical researchers
Summary
Black Hills Regional Eye Institute is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Glaucoma, Cystoid Macular Edema and other specialties. Black Hills Regional Eye Institute is involved with conducting 83 clinical trials across 56 conditions. There are 2 research doctors associated with this hospital, such as Adam Jorgensen, MD and Stephen Khachikian, M.D..Top PIs
Adam Jorgensen, MDBlack Hills Regional Eye Institute3 years of reported clinical research
Studies Open-Angle Glaucoma
Studies Glaucoma
1 reported clinical trial
2 drugs studied
Stephen Khachikian, M.D.Black Hills Regional Eye Institute2 years of reported clinical research
Studies Neurotrophic Keratopathy
1 reported clinical trial
2 drugs studied
Clinical Trials running at Black Hills Regional Eye Institute
Age-Related Macular Degeneration
Choroidal Neovascularization
Macular Degeneration
Retinal Degeneration
Retinal Disease
None
Choroidal neovascularization
Wet AMD
Neurotrophic Keratopathy
RGX-314 Gene Therapy
for Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
Recruiting2 awards Phase 32 criteria
4D-150 + EYLEA
for Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Recruiting2 awards Phase 34 criteria
RGX-314 Gene Therapy
for Wet Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Recruiting1 award Phase 2 & 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Black Hills Regional Eye Institute?
Black Hills Regional Eye Institute is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Glaucoma, Cystoid Macular Edema and other specialties. Black Hills Regional Eye Institute is involved with conducting 83 clinical trials across 56 conditions. There are 2 research doctors associated with this hospital, such as Adam Jorgensen, MD and Stephen Khachikian, M.D..
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.